Evidence map›Paper›PMID 42567511›Full record

ArticleThe Journal of biological chemistry2026

O-mannosylation and furin processing are critical maturation events for the KIAA1549 protein implicated in pediatric pilocytic astrocytomas.

Gloria Kyrila, Serpil Ahmed, Anna Borgenvik, Daniel Christen, Sean A Misek, Alexander Zhang, Sanae Furukawa, Hiren J Joshi, Yoshiki Narimatsu, Rameen Beroukhim and 2 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gloria KyrilaCopenhagen Center for Glycomics & Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Serpil AhmedCopenhagen Center for Glycomics & Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Anna BorgenvikDana-Farber/ Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Daniel ChristenDana-Farber/ Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA; Institute of Molecular Medicine, ZBMZ, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Sean A MisekBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Alexander ZhangDana-Farber/ Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Sanae FurukawaCopenhagen Center for Glycomics & Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Hiren J JoshiCopenhagen Center for Glycomics & Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Yoshiki NarimatsuCopenhagen Center for Glycomics & Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
Rameen BeroukhimBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Pratiti BandopadhayayDana-Farber/ Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, USA; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Adnan HalimCopenhagen Center for Glycomics & Center for Glycocalyx Research, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark. Electronic address: halim@sund.ku.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gene fusion KIAA1549::BRAF is a common oncogenic driver in pediatric pilocytic astrocytoma. The chimeric fusion protein that comprises most of the type 1 transmembrane KIAA1549 protein fused in its C-terminal cytosolic domain to the truncated BRAF oncogene without its N-terminal autoinhibitory domains. KIAA1549 has a large N-terminal ectodomain that undergoes extensive O-mannosylation directed by the POMT1/2 protein O-mannosyltransferase complex localized in the ER. Here, we investigated how posttranslational modifications contribute to KIAA1549 protein maturation in the secretory pathway. Using a panel of KIAA1549 expression constructs and glycoengineered HEK293 cells, we provide evidence that O-mannosylation of the KIAA1549 ectodomain is required for ER exit, acquisition of complex N-glycans, and subsequent furin-like cleavage in the Golgi. In the absence of POMT1/2 O-mannosylation KIAA1549 is retained in ER and fails to undergo proprotein processing. Our findings confirm and extend our previous studies with the KIAA1549::BRAF fusion protein, where oncogenic transformation was dependent on POMT1/2 O-mannosylation and affected on furin processing. Thus, these intrinsic posttranslational modifications of the KIAA1549 ectodomain are critical determinants of the cellular trafficking that lead to activation of the BRAF oncogene, potentially involving a cascade of cleavage events in the Golgi that ultimately release a truncated but fully active BRAF kinase domain into the cytosol.

Indexed as

ER-Golgi traffickingfurin processingKIAA1549KIAA1549::BRAF fusionO-mannosylationoncogenic signalingpediatric pilocytic astrocytomaPOMT1/POMT2protein glycosylationprotein maturation

Identifiers

PMID42567511
PMCPMC13570299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.